These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 26161708

  • 1. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis.
    Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Nafissi S, Togha M, Beladi Moghadam N, Roostaei T, Siassi F, Eshraghian MR, Ghanaati H, Jafarirad S, Rafiei B, Harirchian MH.
    Arch Iran Med; 2015 Jul; 18(7):435-40. PubMed ID: 26161708
    [Abstract] [Full Text] [Related]

  • 2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
    Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ.
    Neurology; 2011 Oct 25; 77(17):1611-8. PubMed ID: 22025459
    [Abstract] [Full Text] [Related]

  • 4. Effect of Vitamin A Supplementation on fatigue and depression in Multiple Sclerosis patients: A Double-Blind Placebo-Controlled Clinical Trial.
    Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Soltani D, Nafissi S, Togha M, Beladi Moghadam N, Roostaei T, Mohammadzadeh Honarvar N, Harirchian MH.
    Iran J Allergy Asthma Immunol; 2016 Feb 25; 15(1):13-9. PubMed ID: 26996107
    [Abstract] [Full Text] [Related]

  • 5. Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial.
    Shaygannejad V, Janghorbani M, Savoj MR, Ashtari F.
    Neurol Res; 2010 Nov 25; 32(9):981-5. PubMed ID: 20223094
    [Abstract] [Full Text] [Related]

  • 6. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J.
    JAMA; 2015 Jan 20; 313(3):275-84. PubMed ID: 25602998
    [Abstract] [Full Text] [Related]

  • 7. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 04; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S, Azimi A, Amini-Harandi A, Salami S, shahkarami MA, Heshmat R.
    Clin Neurol Neurosurg; 2012 Sep 04; 114(7):986-9. PubMed ID: 22429566
    [Abstract] [Full Text] [Related]

  • 13. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 04; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 14. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S, Ormeci B, Idiman E.
    J Neurol Sci; 2005 May 15; 232(1-2):65-9. PubMed ID: 15850584
    [Abstract] [Full Text] [Related]

  • 15. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, Riddehough A, Li DK, McDougall J, Lovera J, Murchison C, Bourdette D.
    Mult Scler Relat Disord; 2016 Sep 15; 9():80-90. PubMed ID: 27645350
    [Abstract] [Full Text] [Related]

  • 16. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.
    Mult Scler Relat Disord; 2014 Nov 15; 3(6):696-704. PubMed ID: 25891548
    [Abstract] [Full Text] [Related]

  • 17. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 15; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B.
    Eur J Neurol; 2008 Mar 10; 15(3):284-8. PubMed ID: 18290849
    [Abstract] [Full Text] [Related]

  • 20. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.